The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population

Yun, Seok‐Joong; Ha, You-Kyoung; Chae, Younbyoung; Kim, J.S.; Kim, I.Y.; Kim, W.J.

doi:10.1093/annonc/mdr115

Cited by 21 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, to ensure that as many eligible studies were included as possible, the reference lists in the articles were checked; 1 study with accessible data was discovered (19). Finally, 11 qualifying studies were included in this meta-analysis (8, 17–26) (Tab. I).…”

Section: Resultsmentioning

confidence: 99%

HOGG1 C1245G Gene Polymorphism Associated with Prostate Cancer: A Meta-Analysis

Yang

et al. 2015

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

HOGG1 C1245G Gene Polymorphism Associated with Prostate Cancer: A Meta-Analysis

Yang

et al. 2015

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…According to the inclusion criteria, a total of 26 data sets (6 for XPD Asp312Asn [8,9,11,12,14,15], 7 for XPD Lys751Gln [8,11,12,14,15,16,17], and 9 for hOGG1 Ser326Cys [8,9,10,18,19,20,21,22,23]) were identiﬁed from 15 eligible papers. In total, 5,765 cases and 6,270 controls (Asp312Asn, 2,714 cases and 3,307 controls; Lys751Gln, 3,271 cases and 3,578 controls, and Ser326Cys, 3,951 cases and 4,043 controls) were included in our study.…”

Section: Resultsmentioning

confidence: 99%

Polymorphisms in XPD and hOGG1 and Prostate Cancer Risk: A Meta-Analysis

et al. 2012

View full text Add to dashboard Cite

Objective: To examine the association between XPD and hOGG1 polymorphisms and prostate cancer (PCa) susceptibility. Methods: A comprehensive search was conducted to identify all case-control studies on the relationship between XPD and hOGG1 polymorphisms and PCa risk. Odds ratios (ORs) were used to investigate the strength of the associations. Results: A total of 15 case-control studies including 5,765 cases and 6,270 controls were eligible for the meta-analyses. For XPD Asp312Asn, no evidence indicated that individuals carrying 312Asn had an increased risk of PCa. In subgroup analyses, Asp312Asn polymorphism was associated with PCa risk in Asian populations [OR = 2.09 and 95% CI = 1.39–3.14 for Asn/Asn vs. Asp/Asp; OR = 1.49 and 95% CI = 1.12–1.98 for (Asn/Asn+Asn/Asp) vs. Asp/Asp]. For XPD Lys751Gln, the individuals with 751Gln did not have increased PCa risk compared with those with 751Arg, and no association was found in the subgroup analyses. For hOGG1 Ser326Cys, no significant association between the polymorphism and PCa risk was observed in the overall analysis. However, Ser326Cys was significantly associated with PCa risk under homologous contrast in Caucasians and Asians. Conclusions: XPD Asp312Asn polymorphism is associated with PCa risk in Asians and hOGG1 Ser326Cys polymorphism is associated with PCa risk in Caucasians and Asians.

show abstract

“…Prior to identification of “third generation” EGFR TKIs, the most promising targeted regimen in patients with acquired resistance had been the combination of afatinib plus cetuximab, which induced a 32% response rate and median progression-free survival of 4.7 months in a heavily pre-treated cohort (52) with a significant degree of skin and gastrointestinal (diarrhea) toxicity. In the phase I trial of AZD9291 in EGFRm+ NSCLC patients that had progressed on earlier generation TKIs, evidence of efficacy has been seen at all doses studied so far, with AZD9291 induced partial radiographic responses in patients whose tumors were known to harbor T790M, from the first dose cohort onwards (49, 53).…”

Section: Discussionmentioning

confidence: 99%

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross¹,

Ashton²,

Ghiorghiu³

et al. 2014

Cancer Discovery

1,814

1,559

View full text Add to dashboard Cite

First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resistance mutation. AZD9291 is a novel oral, potent and selective third generation irreversible inhibitor of both EGFRm+ sensitizing and T790M resistance mutants that spares wild-type EGFR. This monoanilino-pyrimidine compound is structurally distinct from other third generation EGFR TKIs and offers a pharmacologically differentiated profile from earlier generation EGFR TKIs. Pre-clinically, the drug potently inhibits signaling pathways and cellular growth in both EGFRm+ and EGFRm+/T790M mutant cell lines in vitro, with lower activity against wild-type EGFR lines, translating into profound and sustained tumor regression in EGFR mutant tumor xenograft and transgenic models. The treatment of two patients with advanced EGFRm T790M+ NSCLC is described as proof of principle.

show abstract

The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population

Abstract: These results suggest that hOGG1 is associated with the susceptibility to CaP and its aggressive clinicopathological characteristics.

Cited by 21 publications

References 23 publications

HOGG1 C1245G Gene Polymorphism Associated with Prostate Cancer: A Meta-Analysis

HOGG1 C1245G Gene Polymorphism Associated with Prostate Cancer: A Meta-Analysis

Polymorphisms in XPD and hOGG1 and Prostate Cancer Risk: A Meta-Analysis

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Contact Info

Product

Resources

About